WE DEVELOP IT.CHARTS CONTENTSCHARTS. 2-3 ENGINE.
4-59 INTAKE.60-71 EXHAUST.72-81 TRANSAXLE.82-89 INTERIOR.90-109 EXTERIOR. 110-125 CHASSIS.126-135 SUSPENSION.136-145 TOOLS/BOOKS.146-155 WATERCOOLED.156-157 INDEX.158-159 TERMS. 160 PROMOTIONAL. IBCWhenever there is a quality product or trick solution needed, you can always count on the staff at BUGPACK to come through. Weve been developing and producing the highest quality products since 1968.
In fact, many of the industrys most innovative and influential products and advances in technology originated right here at BUGPACK products. Before any product receives the approval to be considered a BUGPACK product, it undergoes rigorous testing procedures allowing you to buy with confidence. It is for this reason that youll find that many of the top performing race cars are proud to wear the BUGPACK name. Cal-Look Window Rubber, High Performance Heads, Off Road Chassis Kits, Off Road and Performance Street Exhaust Systems,OilPumps,OnePiece Snap-InWindowKits,Urethane Bushings & Mounts, Rocker Arms&Shafts,Aluminum Dash Panels and Intake Manifolds are just a few of the items produced and manufactured in house at one of our two facilities.
Hamilton beach 40616 manuals; Sentry safe v332 manual muscle; Nokia c7 manually reset ipad. Af 300 mini users manual for a coleman powermate 024-0202. Manuales organizativos de una empresaria; Waves h eq manuals; Bosch ascenta she3ar52uc manual; Wzmacniacz technics su-v670 service manual; Seguin form board test manuals; Emerson 100 kva.
The ability to employ stringent quality control methods on all of our products ensures that the product you receive is of the highest quality.WE TEST IT.WE BUILD IT.WE HAVE IT.With a great selection of aftermarket VW high performance parts and cool accessories, BUGPACK provides your needs. In addition to our own extensive product line we also stock and distribute other fine products such as.Mahle Pistons and Cylinder Sets, Sway-A-Way suspension parts, EngleCams,WeberCarbs,K&NFilters,VDO Gauges,KennedyEngineeringProducts,KYB Shocks, Robert Bently Manuals, Crow Safety Equipment Outerwears and SPTools among other well known quality brands.WE SUPPORT IT.Often in the industry today it seems that once a product leaves the facility.thats it, youre on your own.
Not at BUGPACK Products.We offer support 5 days a week on every product we sell. In most cases our extensive dealer network is able to answer any question you may have. With virtually every product shipping with complete and detailed instructions (So complete that often our competitors simply copy them) and all the correct hardware. We are confident that the installation of your new BUGPACK product will be completed swiftly and correctly.
However, we do understand that you may have some installation concerns, so be assured.were always here for you!
The invention provides novel polynucleotides and polypeptides associated with the incidence of PPAR-agonist induced edema. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides which comprise at least one polymorphic locus per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel polynucleotides and polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders, particularly PPAR-agonist induced edema or related indications.
The invention further relates to screening methods for identifying agonists of PPAR proteins with decreased risk of inducing peripheral edema in patients. 3 2005-12-29 Rusowicz et al. 64-07-02 Cheng et al. 60-02-22 Unger 59-10-19 McCafferty et al. 59-08-17 Kucherlapati et al. 59-06-29 Hori et al. 58-03-23 Griffiths et al.
58-02-23 Rava et al. 58-01-12 Sapolsky et al. 58-01-05 Lipshutz et al.
58-01-05 Chee et al. 58-11-17 Chee et al. 58-10-13 Garrard et al. 58-09-29 Lonberg et al. 58-09-15 Morrison et al. 57-07-14 Wigler et al.
57-05-12 Kimae et al. 57-03-31 Treco et al. 57-03-31 Johnson et al. 57-02-10 Srinivasan et al. 56-12-16 Huse 56-08-26 Baumann et al.
56-08-26 Lonberg et al. 56-08-19 Barbas et al. 56-06-24 Treco et al. 56-05-27 Lonberg et al. 56-04-29 Lonberg et al. 56-04-22 Willner et al.
56-02-11 Wong et al. 55-12-17 Queen et al. 55-12-03 Dower et al.
55-11-12 Randle 55-11-05 Ladner et al. 55-10-29 Lonberg et al.
55-10-15 Hoogenboom et al. 55-08-13 Surani et al. 55-08-13 Lonberg et al. 55-06-25 Queen et al.
55-05-14 Huang et al. 54-12-26 Wallach et al.
54-12-12 Leder et al. 54-09-05 Beutler et al. 54-08-15 Thurston et al. 54-06-27 Dower et al. 54-05-09 Kucherlapati et al. 54-04-04 Ladner et al. 53-10-25 Capon et al.
53-09-20 Landolfi 53-08-09 Capon et al. 53-05-24 Fell, Jr. 52-11-02 Huston et al. 52-07-06 Winter 52-06-29 Ladner et al. 52-04-27 Unger 51-06-16 Wilson et al.
51-05-12 Maione 50-12-17 Curtis et al. 49-12-25 Morgan et al.
49-08-07 Ladner et al. 49-05-15 Hansen et al. 48-03-28 Cabilly et al. 48-03-28 Boss et al.
47-05-03 Alvarez et al. 47-12-29 Osband et al. 47-12-22 Reading 46-07-28 Mullis et al. 46-06-30 Segal et al. 46-12-23 Houghten 44-10-02 Reading 44-04-24 Hoffmann 43-03-08 David et al. 41-12-18 Davis et al.
What is claimed is: 1. A method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema in a patient comprising the step of: (a) incubating mammalian cells that endogenously express renin with a test compound; and (b) measuring the level of induced expression of renin mRNA in response to said test compound; wherein a decreased level of induced renin mRNA expression by said test compound relative to a reference compound is indicative of a decreased risk of said test compound inducing dose-dependent peripheral edema in a patient. The method according to claim 1, wherein said cells are human CALU-6 cells. The method according to claim 1, further comprising the step of measuring the level of induced expression of endothelin-1 mRNA in response to said test compound wherein said cells endogenously express endothelin-1; and wherein an increased level of induced endothelin-1 expression by the test compound relative to a reference compound is indicative of a decreased risk of said compound inducing dose-dependent peripheral edema in a patient.
The method according to claim 3, wherein said cells are human CALU-6 cells. The method according to claim 1, wherein the measurement of human renin mRNA expression is performed using the polymerase chain reaction. The method according to claim 1, wherein the measurement of human renin mRNA expression is performed using the quantitative polymerase chain reaction. The method according to claim 1, wherein the measurement of human renin mRNA expression is performed using the reverse-transcribed polymerase chain reaction.
The method according to claim 1, wherein the measurement of human renin mRNA expression is performed using microarrays. The method according to claim 1, wherein the measurement of human renin mRNA expression is performed using mass spectrometry. A method according to claim 1, wherein said renin mRNA encodes the renin polypeptide with one amino acid substitution.
A method according to claim 3, wherein said endothelin-1 mRNA encodes the endothelin-1 polypeptide with one amino acid substitution.
Comments are closed.
|
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |